Rapidly progress your immuno-oncology drug development programs with our highly experienced screening platform.

Choose MuScreen to:

- Screen agents using well-characterized syngeneic and tumor homograft models, with ICI benchmarking, baseline tumor immune profile, and tumor RNAseq data available.
- Evaluate single or combination agent strategies.
- Efficiently identify responder models.
- Uncover mechanism of action and predictive biomarkers.
- Benefit from CrownBio covering the cost of the vehicle group for all models.

**Syngeneic Model Panels**
Choose our well-characterized syngeneic model panels, displaying heterogeneous immune phenotypes, for rapid and large scale compound efficacy or PD evaluation.

**Tumor Homograft Panel**
Choose our unique tumor homograft models featuring clinically relevant mutations, for single agent immunotherapy and combination I/O and targeted agent efficacy assessment.

Our unique MuPrime™ tumor homografts are transplants of spontaneous or carcinogen-induced GEMM tumors in immunocompetent syngeneic hosts:

- Carrying disease-relevant oncogenic mutations of human cancers including KRAS, PTEN, and TP53.
- Preserving original GEMM tumor histo- and molecular pathology.

---

A JSR Life Sciences Company

+1.855.827.6968 | busdev@crownbio.com | www.crownbio.com

---